Skip to main content
SpringerLink
Log in

GSK bets on the genomic route to drug safety

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

GSK bets on the genomic route to drug safety. Pharmacoecon. Outcomes News 302, 3–4 (2001). https://doi.org/10.1007/BF03280184

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03280184

Keywords

Search

Navigation